NCT07077057 Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction
| NCT ID | NCT07077057 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cardiocentro Ticino |
| Condition | Myocardial Infarction (MI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-08-23 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2025-08-23 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with suspected acute coronary syndrome (ACS) who do not meet traditional ST-elevation myocardial infarction (STEMI) criteria. The main questions it aims to answer are: 1. Does AI-assisted ECG interpretation enable more timely identification and treatment of OMI, as defined by earlier initiation of coronary intervention? 2. Does AI-assisted diagnosis reduce infarct size, measured by peak high-sensitivity troponin T (hsTnT) levels? Researchers will compare AI-assisted ECG interpretation to standard care to determine if the AI tool improves clinical outcomes and care timelines. Participants will: 1. Present with symptoms suggestive of ACS but without clear STEMI criteria 2. Be randomized 1:1 to either AI-assisted or standard ECG interpretation 3. Undergo follow-up assessments for cardiovascular outcomes, including 30-day death, time to treatment of total coronary occlusion, and peak hsTnT levels
Eligibility Criteria
Inclusion Criteria: 1. Symptoms suspected of ongoing acute myocardial ischemia: Patients presenting with symptoms such as chest pain, dyspnoea, sweating, nausea or vomiting, pain radiating to the shoulder/arm/jaw/back, fatigue, or light-headedness 2. Age: Patients aged 18 years or older. 3. Informed Consent: Patients able to provide informed consent Exclusion Criteria: 1. Clear diagnosis of ST-segment elevation MI (STEMI) according to managing physicians. 2. Pregnancy or Lactation. 3. Legally incompetent to provide informed consent. 4. Symptoms onset\>24 hrs prior to clinical presentation.
Frequently Asked Questions
Who can join the NCT07077057 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myocardial Infarction (MI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07077057 currently recruiting?
Yes, NCT07077057 is actively recruiting participants. Visit ClinicalTrials.gov or contact Cardiocentro Ticino to inquire about joining.
Where is the NCT07077057 trial being conducted?
This trial is being conducted at Lugano, Switzerland.
Who is sponsoring the NCT07077057 clinical trial?
NCT07077057 is sponsored by Cardiocentro Ticino. The trial plans to enroll 500 participants.